Goldman Sachs Alternatives will partner with BC Partners and Synthon’s management to support Synthon’s mission of enabling affordable medicines for patients globally and back the company’s next stage of growth, focused on advancing existing products and launching new medicines by way of leveraging Synthon’s differentiated, science-backed, intellectual property-driven development platform.
Headquartered in the Netherlands, Synthon has approximately 1,600 employees and operates four research laboratories and four manufacturing sites located in the Czech Republic, Spain, Chile, and Argentina. Founded in 1991, Synthon now operates across a diversified base of more than 200 customers across around 100 countries, supplying high-quality complex generic pharmaceuticals based upon its differentiated intellectual property strategy.
The A&O Shearman sponsor side leveraged finance team was led by partner Nick Hallam together with global co-head of private equity Robin Harvey, alongside senior associate Dhruv Mairal and associates Jack Mellett, Ramone Bedi and Nahima Parvin.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
